Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crosslinked HA with Liposomes vs Linear HA for Dry Eye
NCT03617315Completed
- Sponsor
- University of Seville
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Device-based Delivery, Hydrogel Systems, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Randomised, single-blind trial of Lumixa in dry eye disease (DED) and meibomian gland dysfunction (MGD) (2 arms), sponsored by University of Seville. Primary endpoints: Schirmer Test at 6 weeks, Break Up Time Test at 6 weeks and 1 more. Started Oct 2017; status: completed.
02
Drugs
Lumixa
03
Conditions
dry eye disease (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT03617315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617315.